DWA
VKTX icon

Dorsey Wright & Associates’s Viking Therapeutics VKTX Stock Holding History

Dorsey Wright & Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,660
Closed -$46K – 350
2018
Q3 		$46K Buy
+2,660
New +$31.7K 0.01% 118

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dorsey Wright & Associates's VKTX Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Viking Therapeutics (VKTX) in Q4 2018, closing a stake of 2,660 shares — an estimated $46K sold.

Dorsey Wright & Associates first reported a position in VKTX in Q3 2018 and held it in 1 quarter. The position peaked at $46K in Q3 2018. 168 funds tracked by Wall St. Rank hold VKTX as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Viking Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,660 Viking Therapeutics shares in Q4 2018, an estimated $46K.
  • Dorsey Wright & Associates first reported a position in Viking Therapeutics in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Viking Therapeutics position peaked at $46K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.